Hameed Abdul, Ali Jamshed, Munawar Kiran, Arshad Farah, Badar Farhana, Siddiqui Neelam
Department of Medical Oncology, Shaukat Khanum Cancer Hospital and Research Centre, Pakistan.
Deapartment of Cancer Registry and Data Management, Shaukat Khanum Cancer Hospital and Research Centre, Lahore, Pakistan.
Med J Islam Repub Iran. 2018 Feb 1;32:1. doi: 10.14196/mjiri.32.1. eCollection 2018.
Multiple myeloma (MM) is a plasma cell disorder characterized by presence of monoclonal protein in serum or urine or both, increased bone marrow plasma cells, osteolytic lesion, hypercalcemia, and anemia. Several combination regimens are commonly recommended for treatment of multiple myeloma. The present study aimed at determining the characteristics and outcomes of patients with multiple myeloma treated at our centre. During July 2012 and December 2015, all patients with proven diagnosis of MM were included in this study. Data were collected from hospital information system. The characteristics and outcomes of all patients were analyzed. Progression- free survival and overall survival of patients were also estimated. Kaplan-Meier curves and Log-rank test were applied and SPSS Version19 was used for data analysis. A total of 82 patients, with the median age of 51 years (Range: 23-64 yrs.) were available for final analysis. The number of patients with IgG and IgA type was 48 (58.5%) and 15(18.3%), respectively. There were 7 (8.5%) patients with non-secretory type. Most of the patients (n= 59; 71.9%) were treated with CTD regimen and 13 (15.8%) received bortezomib-based treatment. The median progression-free survival time was 30 months, and overall survival time was 48 months. The cumulative probability of survival at 36 months was 85%. Based on our results, the onset of multiple myeloma occurs in relatively younger age groups. A small number of patients received bortezomib due to cost issues. PFS and OS in our study were comparable with published literature.
多发性骨髓瘤（MM）是一种浆细胞疾病，其特征为血清或尿液中存在单克隆蛋白，或两者皆有，骨髓浆细胞增多、溶骨性病变、高钙血症和贫血。几种联合治疗方案通常被推荐用于多发性骨髓瘤的治疗。本研究旨在确定在我们中心接受治疗的多发性骨髓瘤患者的特征和治疗结果。在2012年7月至2015年12月期间，所有确诊为MM的患者均纳入本研究。数据从医院信息系统收集。分析了所有患者的特征和治疗结果。还估计了患者的无进展生存期和总生存期。应用Kaplan-Meier曲线和Log-rank检验，并使用SPSS 19版进行数据分析。共有82例患者可供最终分析，中位年龄为51岁（范围：23 - 64岁）。IgG型和IgA型患者分别有48例（58.5%）和15例（18.3%）。有7例（8.5%）患者为非分泌型。大多数患者（n = 59；71.9%）接受了CTD方案治疗，13例（15.8%）接受了基于硼替佐米的治疗。中位无进展生存时间为30个月，总生存时间为48个月。36个月时的累积生存概率为85%。根据我们的研究结果，多发性骨髓瘤发病于相对年轻的年龄组。由于费用问题，少数患者接受了硼替佐米治疗。我们研究中的无进展生存期和总生存期与已发表的文献相当。
